Effects of donitriptan on carotid haemodynamics and cardiac output distribution in anaesthetized pigs

被引:8
作者
Tom, B
De Vries, P
Heiligers, JPC
Willems, EW
Kapoor, K
John, GW
Saxena, PR
机构
[1] Erasmus Univ, Med Ctr Rotterdam, Dept Pharmacol, Dutch Migraine Res Grp, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr Rotterdam, Cardiovasc Res Inst COEUR, NL-3000 DR Rotterdam, Netherlands
[3] Ctr Rech Pierre Fabre, Div Cardiovasc Dis, F-81106 Castres, France
关键词
5-HT1B/1D receptors; arteriovenous anastomoses; cardiac output; donitriptan; migraine;
D O I
10.1046/j.1468-2982.2002.00308.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We investigated the effects of donitriptan, which possesses a uniquely high affinity and efficacy at 5-HT1B/1D receptors, on carotid and systemic haemodynamics in anaesthetized pigs, Donitriptan (0.16-100 mug kg(-1), i.v.) dose-dependently decreased total carotid blood flow and vascular conductance (maximum response: -25+/-3%). This effect was entirely due to a selective reduction in the cephalic arteriovenous anastomotic fraction (maximum response: -63+/-3%; ED50%; 92+/-31 nmol/kg); the nutrient vascular conductance increased. Donitriptan did not decrease vascular conductances in or blood flow to a number of organs, including the heart and kidneys; in fact, vascular conductances in the skin, brain and skeletal muscles increased. Cardiac output was slightly decreased by donitriptan, but this effect was confined to peripheral arteriovenous anastomoses. The haemodynamic effects of donitriptan were substantially reduced by the 5-HT1B/1D receptor antagonist GR127935. These results show that donitriptan selectively constricts arteriovenous anastomoses via 5-HT1B receptor activation. The drug should be able to abort migraine headaches and it is unlikely to compromize blood Row to vital organs.
引用
收藏
页码:37 / 47
页数:11
相关论文
共 44 条
[21]  
Humphrey P.P.A., 1990, CARDIOVASCULAR PHARM, P416
[22]   GR43175, A SELECTIVE AGONIST FOR THE 5-HT1-LIKE RECEPTOR IN DOG ISOLATED SAPHENOUS-VEIN [J].
HUMPHREY, PPA ;
FENIUK, W ;
PERREN, MJ ;
CONNOR, HE ;
OXFORD, AW ;
COATES, IH ;
BUTINA, D .
BRITISH JOURNAL OF PHARMACOLOGY, 1988, 94 (04) :1123-1132
[23]  
John GW, 1999, J PHARMACOL EXP THER, V290, P83
[24]  
John GW, 2000, CNS DRUG REV, V6, P278
[25]  
MARTIN GR, 1998, IUPHAR COMPENDIUM RE, P169
[26]   NEUROGENIC VERSUS VASCULAR MECHANISMS OF SUMATRIPTAN AND ERGOT ALKALOIDS IN MIGRAINE [J].
MOSKOWITZ, MA .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (08) :307-311
[27]   Contractile 5-HT1B receptors in human cerebral arteries:: pharmacological characterization and localization with immunocytochemistry [J].
Nilsson, T ;
Longmore, J ;
Shaw, D ;
Olesen, IJ ;
Edvinsson, L .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (06) :1133-1140
[28]  
Pauwels P.J, 1996, CNS DRUG REV, V2, P415
[29]   How efficacious are 5-HT1B/D receptor ligands: An answer from GTP gamma S binding studies with stably transfected C6-glial cell lines [J].
Pauwels, PJ ;
Tardif, S ;
Palmier, C ;
Wurch, T ;
Colpaert, FC .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :499-512
[30]  
Razzaque Z, 1999, BRIT J CLIN PHARMACO, V47, P75